Atreca, a preclinical biotech developing immunotherapies for solid tumors, raised $125 million by offering 7.4 million shares at $17, the midpoint of the $16 to $18 range. Existing investors had indicated an interest in buying up to $60 million on the IPO (48% of the deal).
Atreca plans to list on the Nasdaq under the symbol BCEL. Cowen, Evercore ISI and Stifel acted as lead managers on the deal.
